GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Taysha Gene Therapies Inc (NAS:TSHA) » Definitions » PB Ratio

Taysha Gene Therapies (Taysha Gene Therapies) PB Ratio : 10.36 (As of May. 21, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Taysha Gene Therapies PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-21), Taysha Gene Therapies's share price is $2.985. Taysha Gene Therapies's Book Value per Share for the quarter that ended in Mar. 2024 was $0.29. Hence, Taysha Gene Therapies's PB Ratio of today is 10.36.

The historical rank and industry rank for Taysha Gene Therapies's PB Ratio or its related term are showing as below:

TSHA' s PB Ratio Range Over the Past 10 Years
Min: 3.59   Med: 8.61   Max: 153.33
Current: 10.29

During the past 5 years, Taysha Gene Therapies's highest PB Ratio was 153.33. The lowest was 3.59. And the median was 8.61.

TSHA's PB Ratio is ranked worse than
89.57% of 1323 companies
in the Biotechnology industry
Industry Median: 2.53 vs TSHA: 10.29

During the past 3 years, the average Book Value Per Share Growth Rate was -60.80% per year.

During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of Taysha Gene Therapies was -60.80% per year. The lowest was -60.80% per year. And the median was -60.80% per year.

Back to Basics: PB Ratio


Taysha Gene Therapies PB Ratio Historical Data

The historical data trend for Taysha Gene Therapies's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taysha Gene Therapies PB Ratio Chart

Taysha Gene Therapies Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
- 3.99 4.70 150.67 4.41

Taysha Gene Therapies Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 4.41 9.97

Competitive Comparison of Taysha Gene Therapies's PB Ratio

For the Biotechnology subindustry, Taysha Gene Therapies's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Taysha Gene Therapies's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Taysha Gene Therapies's PB Ratio distribution charts can be found below:

* The bar in red indicates where Taysha Gene Therapies's PB Ratio falls into.



Taysha Gene Therapies PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Taysha Gene Therapies's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2024)
=2.985/0.288
=10.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Taysha Gene Therapies  (NAS:TSHA) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Taysha Gene Therapies PB Ratio Related Terms

Thank you for viewing the detailed overview of Taysha Gene Therapies's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Taysha Gene Therapies (Taysha Gene Therapies) Business Description

Traded in Other Exchanges
N/A
Address
3000 Pegasus Park Drive, Suite 1430, Dallas, TX, USA, 75247
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. It is advancing a deep and sustainable product portfolio of 18 gene therapy product candidates, with exclusive options to acquire four additional development programs. Its product candidates include TSHA-101, TSHA-118, TSHA-102, TSHA-103, and TSHA-104.
Executives
Paul B Manning director, 10 percent owner 200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Alison S Long director KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVENUE, LEXINGTON MA 02421
Kamran Alam officer: Chief Financial Officer 350 FIFTH AVENUE, SUITE 7530, NEW YORK NY 10118
Sean P. Nolan director C/O INTERMUNE, INC., 3280 BAYSHORE BLVD., BRISBANE CA 94005
Phillip B. Donenberg director C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015
Stalfort John A Iii director C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Session R.a. Ii 10 percent owner C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015
Sukumar Nagendran director C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 160, BANNOCKBURN IL 60015
Astellas Pharma Inc. 10 percent owner 2-5-1, NIHONBASHI-HONCHO, CHUO-KU, TOKYO M0 103-8411
Audentes Therapeutics, Inc. 10 percent owner 600 CALIFORNIA ST., 17TH FLOOR, SAN FRANCISCO CA 94108
Suyash Prasad officer: CMO and Head of R&D C/O AUDENTES THERAPEUTICS, INC., 101 MONTGOMERY ST., SUITE 2650, SAN FRANCISCO CA 94104
Laura Sepp-lorenzino director C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139
Kathleen Reape director C/O TAYSHA GENE THERAPIES, INC., 2280 INWOOD ROAD, DALLAS TX 75235

Taysha Gene Therapies (Taysha Gene Therapies) Headlines

From GuruFocus